SCHEMBL19968873

SCHEMBL19968873

CC1CCN(c2cccc(S(=O)(=O)Nc3ccc(C(F)(F)F)c(-c4ccccc4C4CCC4)n3)n2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.36
HSD11B1 P28845 2/20 0.36
SCN1A P35498 4/20 0.34
SCN8A Q9UQD0 4/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
MAPK1 P28482 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
CTSS P25774 1/20 0.33
RBP4 P02753 4/20 0.33
TP53 P04637 1/20 0.33
THRB P10828 1/20 0.33
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968816 0.98 SCN9A (0.36) SCN9AHSD11B1SCN1ASCN8AGAA
SCHEMBL22323149 0.88 FFAR4 (0.39) SCN9AHSD11B1SCN1ASCN8ARBP4
SCHEMBL19951319 0.88 RORC (0.33) SCN9AHSD11B1SCN1ASCN8ARBP4
SCHEMBL19968826 0.87 CYP1A2 (0.41) SCN9ASCN1ASCN8AKDM4ECTSS
SCHEMBL19968876 0.86 SCN9A (0.39) SCN9AGAAMAPTMAPK1L3MBTL1
SCHEMBL19925129 0.86 RORC (0.33) SCN9AHSD11B1SCN1ASCN8ARBP4
SCHEMBL24360683 0.86 RBP4 (0.34) SCN9AHSD11B1SCN1ASCN8ARBP4
SCHEMBL19968882 0.85 SCN1A (0.37) SCN9AHSD11B1SCN1ASCN8AGAA
SCHEMBL23748044 0.85 RBP4 (0.36) SCN9ASCN1ASCN8AGAAKDM4E
SCHEMBL29464381 0.85 IDH2 (0.38) SCN9AHSD11B1RBP4SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 SCN9A 381/4885HSD11B1 3742/4885SCN1A 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.